Loading...
 
Translate Register Log In Login with facebookLogin and Register

Respiratory infections reduced only 20 percent by Vitamin D (ignored dose size, duration, type, etc) – meta-analysis Jan 2019

Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis

Vitamin D supplementation reduced the risk of acute respiratory infections, with very vitamin D deficient people and those receiving daily or weekly doses experiencing the most benefit.
Health Technology Assessment Vol: 23, Issue: 2, January 2019, https://doi.org/10.3310/hta23020
Martineau A R, Jolliffe D A, Greenberg L, Aloia J F, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde A A, Goodall E C, Grant C C, Janssens W, Jensen M E, Kerley C P, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch D R, Neale R, Rees J R, Simpson S, Stelmach I, Trilok Kumar G, Urashima M, Camargo C A, Griffiths C J & Hooper R L.

VitaminDWiki

Studies in both Breathing and Intervention categories (give vitamin D and see what happens):

Studies in both Breathing and Meta-analysis categories (summaries of many trials):

 Download the PDF from VitaminDWiki

Dose sizes ranged from 300 IU - 4,000 IU

Note: 4,000 IU is where benefits of Vitamin D are noticed in adults

Image Image Image

They incorrectly label a no response to Vitamin D as a bad outcome

Image

Background: Randomised controlled trials (RCTs) exploring the potential of vitamin D to prevent acute respiratory infections have yielded mixed results. Individual participant data (IPD) meta-analysis has the potential to identify factors that may explain this heterogeneity.

Objectives: To assess the overall effect of vitamin D supplementation on the risk of acute respiratory infections (ARIs) and to identify factors modifying this effect.

Data sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials Number (ISRCTN) registry.

Study selection
Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration having incidence of acute respiratory infection as a prespecified efficacy outcome were selected.

Study appraisal
Study quality was assessed using the Cochrane Collaboration Risk of Bias tool to assess sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity.

Results
We identified 25 eligible RCTs (a total of 11,321 participants, aged from 0 to 95 years). IPD were obtained for 10,933 out of 11,321 (96.6%) participants. Vitamin D supplementation reduced the risk of ARI among all participants [adjusted odds ratio (aOR) 0.88, 95% confidence interval (CI) 0.81 to 0.96; heterogeneity p < 0.001]. Subgroup analysis revealed that protective effects were seen in individuals receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91), but not in those receiving one or more bolus doses (aOR 0.97, 95% CI 0.86 to 1.10; p = 0.05). Among those receiving daily or weekly vitamin D, protective effects of vitamin D were stronger in individuals with a baseline 25-hydroxyvitamin D [25(OH)D] concentration of < 25 nmol/l (aOR 0.30, 95% CI 0.17 to 0.53) than in those with a baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.75, 95% CI 0.60 to 0.95; p = 0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83). The body of evidence contributing to these analyses was assessed as being of high quality.

Limitations: Our study had limited power to detect the effects of vitamin D supplementation on the risk of upper versus lower respiratory infection, analysed separately.

Conclusions: Vitamin D supplementation was safe, and it protected against ARIs overall. Very deficient individuals and those not receiving bolus doses experienced the benefit. Incorporation of additional IPD from ongoing trials in the field has the potential to increase statistical power for analyses of secondary outcomes.

Study registration: This study is registered as PROSPERO CRD42014013953.

Created by admin. Last Modification: Friday January 25, 2019 18:03:50 GMT-0000 by admin. (Version 7)

Attached files

ID Name Comment Uploaded Size Downloads
11265 Good Bad.jpg admin 25 Jan, 2019 12:30 78.37 Kb 79
11264 Dose 3.jpg admin 25 Jan, 2019 12:22 10.70 Kb 61
11263 Dose 2.jpg admin 25 Jan, 2019 12:21 11.60 Kb 63
11262 Dose 1.jpg admin 25 Jan, 2019 12:21 7.33 Kb 63
11261 RTI Meta.pdf PDF 2019 admin 25 Jan, 2019 12:21 951.22 Kb 41
See any problem with this page? Report it (FINALLY WORKS)